Baseline Characteristics of the Participants of the iPrEx and DISCOVER Trials Included in the Complete-Case Analysis
| Characteristic . | IPrEx (n = 2108) . | DISCOVER (n = 4952) . | ||
|---|---|---|---|---|
| Placebo (n = 1049) . | TDF/FTC (n = 1059) . | TDF/FTC (n = 2488) . | TAF/FTC (n = 2464) . | |
| Age category, y | ||||
| 18–24 | 549 (52) | 498 (47) | 265 (11) | 306 (12) |
| 25–29 | 202 (19) | 228 (22) | 520 (21) | 504 (20) |
| 30–34 | 113 (11) | 132 (12) | 488 (20) | 485 (20) |
| 35–39 | 75 (7) | 75 (7) | 368 (15) | 370 (15) |
| 40+ | 110 (10) | 126 (12) | 847 (34) | 799 (32) |
| Not whitea | 861 (82) | 857 (81) | 363 (15) | 353 (14) |
| Hispanic | 749 (71) | 750 (71) | 606 (24) | 568 (23) |
| BMI, kg/m2 b | 23.7 (3.83) | 24.0 (3.99) | 26.2 (4.98) | 26.3 (5.06) |
| Alcohol usec | ||||
| 0 drinks | 163 (16) | 174 (16) | 190 (8) | 225 (9) |
| 1–4 drinks | 306 (29) | 314 (30) | 1914 (77) | 1857 (75) |
| 5+ drinks | 580 (55) | 571 (54) | 384(15) | 382 (16) |
| Number of partners with URAId | ||||
| 0 | 461 (44) | 482 (46) | 595 (24) | 559 (23) |
| 1 | 191 (18) | 185 (17) | 388 (16) | 373 (15) |
| 2 | 87 (8) | 96 (9) | 529 (21) | 496 (20) |
| 3–4 | 111 (11) | 81 (8) | 509 (20) | 514 (21) |
| 5+ | 199 (19) | 215 (20) | 467 (19) | 522 (21) |
| Syphilise | 128 (12) | 128 (12) | 4 (0) | 7 (0) |
| HIV at 96 wkf | 65 (6) | 29 (3) | 14 (1) | 7 (0) |
| Characteristic . | IPrEx (n = 2108) . | DISCOVER (n = 4952) . | ||
|---|---|---|---|---|
| Placebo (n = 1049) . | TDF/FTC (n = 1059) . | TDF/FTC (n = 2488) . | TAF/FTC (n = 2464) . | |
| Age category, y | ||||
| 18–24 | 549 (52) | 498 (47) | 265 (11) | 306 (12) |
| 25–29 | 202 (19) | 228 (22) | 520 (21) | 504 (20) |
| 30–34 | 113 (11) | 132 (12) | 488 (20) | 485 (20) |
| 35–39 | 75 (7) | 75 (7) | 368 (15) | 370 (15) |
| 40+ | 110 (10) | 126 (12) | 847 (34) | 799 (32) |
| Not whitea | 861 (82) | 857 (81) | 363 (15) | 353 (14) |
| Hispanic | 749 (71) | 750 (71) | 606 (24) | 568 (23) |
| BMI, kg/m2 b | 23.7 (3.83) | 24.0 (3.99) | 26.2 (4.98) | 26.3 (5.06) |
| Alcohol usec | ||||
| 0 drinks | 163 (16) | 174 (16) | 190 (8) | 225 (9) |
| 1–4 drinks | 306 (29) | 314 (30) | 1914 (77) | 1857 (75) |
| 5+ drinks | 580 (55) | 571 (54) | 384(15) | 382 (16) |
| Number of partners with URAId | ||||
| 0 | 461 (44) | 482 (46) | 595 (24) | 559 (23) |
| 1 | 191 (18) | 185 (17) | 388 (16) | 373 (15) |
| 2 | 87 (8) | 96 (9) | 529 (21) | 496 (20) |
| 3–4 | 111 (11) | 81 (8) | 509 (20) | 514 (21) |
| 5+ | 199 (19) | 215 (20) | 467 (19) | 522 (21) |
| Syphilise | 128 (12) | 128 (12) | 4 (0) | 7 (0) |
| HIV at 96 wkf | 65 (6) | 29 (3) | 14 (1) | 7 (0) |
Data are No. (%). To be eligible for the complete-case analysis, trial participants had to have no missing data for the reported variables. Furthermore, participants were restricted to men who have sex with men and a subset of the DISCOVER trial.
Abbreviations: BMI, body mass index; FTC, emtricitabine; HIV, human immunodeficiency virus; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; URAI, unprotected receptive anal intercourse.
aRace was measured through self-classification with an open-ended category (iPrEx, DISCOVER). Due to privacy concerns, data from DISCOVER was collapsed to white versus not white. Therefore, iPrEx was similarly collapsed.
bBMI is presented as mean and standard deviation.
cAlcohol use was defined as self-reported number of drinks on days when drinking (iPrEx) or self-reported alcohol intake in drinks per day (DISCOVER).
dSelf-reported number of unique partners with URAI in the past 84 days (iPrEx) or in the past 90 days (DISCOVER) at enrollment.
eBaseline syphilis diagnosis was determined via rapid plasma reagin and a confirmatory test (iPrEx) or diagnosed per local guidelines (DISCOVER).
fPercentages ignore right censoring.
Baseline Characteristics of the Participants of the iPrEx and DISCOVER Trials Included in the Complete-Case Analysis
| Characteristic . | IPrEx (n = 2108) . | DISCOVER (n = 4952) . | ||
|---|---|---|---|---|
| Placebo (n = 1049) . | TDF/FTC (n = 1059) . | TDF/FTC (n = 2488) . | TAF/FTC (n = 2464) . | |
| Age category, y | ||||
| 18–24 | 549 (52) | 498 (47) | 265 (11) | 306 (12) |
| 25–29 | 202 (19) | 228 (22) | 520 (21) | 504 (20) |
| 30–34 | 113 (11) | 132 (12) | 488 (20) | 485 (20) |
| 35–39 | 75 (7) | 75 (7) | 368 (15) | 370 (15) |
| 40+ | 110 (10) | 126 (12) | 847 (34) | 799 (32) |
| Not whitea | 861 (82) | 857 (81) | 363 (15) | 353 (14) |
| Hispanic | 749 (71) | 750 (71) | 606 (24) | 568 (23) |
| BMI, kg/m2 b | 23.7 (3.83) | 24.0 (3.99) | 26.2 (4.98) | 26.3 (5.06) |
| Alcohol usec | ||||
| 0 drinks | 163 (16) | 174 (16) | 190 (8) | 225 (9) |
| 1–4 drinks | 306 (29) | 314 (30) | 1914 (77) | 1857 (75) |
| 5+ drinks | 580 (55) | 571 (54) | 384(15) | 382 (16) |
| Number of partners with URAId | ||||
| 0 | 461 (44) | 482 (46) | 595 (24) | 559 (23) |
| 1 | 191 (18) | 185 (17) | 388 (16) | 373 (15) |
| 2 | 87 (8) | 96 (9) | 529 (21) | 496 (20) |
| 3–4 | 111 (11) | 81 (8) | 509 (20) | 514 (21) |
| 5+ | 199 (19) | 215 (20) | 467 (19) | 522 (21) |
| Syphilise | 128 (12) | 128 (12) | 4 (0) | 7 (0) |
| HIV at 96 wkf | 65 (6) | 29 (3) | 14 (1) | 7 (0) |
| Characteristic . | IPrEx (n = 2108) . | DISCOVER (n = 4952) . | ||
|---|---|---|---|---|
| Placebo (n = 1049) . | TDF/FTC (n = 1059) . | TDF/FTC (n = 2488) . | TAF/FTC (n = 2464) . | |
| Age category, y | ||||
| 18–24 | 549 (52) | 498 (47) | 265 (11) | 306 (12) |
| 25–29 | 202 (19) | 228 (22) | 520 (21) | 504 (20) |
| 30–34 | 113 (11) | 132 (12) | 488 (20) | 485 (20) |
| 35–39 | 75 (7) | 75 (7) | 368 (15) | 370 (15) |
| 40+ | 110 (10) | 126 (12) | 847 (34) | 799 (32) |
| Not whitea | 861 (82) | 857 (81) | 363 (15) | 353 (14) |
| Hispanic | 749 (71) | 750 (71) | 606 (24) | 568 (23) |
| BMI, kg/m2 b | 23.7 (3.83) | 24.0 (3.99) | 26.2 (4.98) | 26.3 (5.06) |
| Alcohol usec | ||||
| 0 drinks | 163 (16) | 174 (16) | 190 (8) | 225 (9) |
| 1–4 drinks | 306 (29) | 314 (30) | 1914 (77) | 1857 (75) |
| 5+ drinks | 580 (55) | 571 (54) | 384(15) | 382 (16) |
| Number of partners with URAId | ||||
| 0 | 461 (44) | 482 (46) | 595 (24) | 559 (23) |
| 1 | 191 (18) | 185 (17) | 388 (16) | 373 (15) |
| 2 | 87 (8) | 96 (9) | 529 (21) | 496 (20) |
| 3–4 | 111 (11) | 81 (8) | 509 (20) | 514 (21) |
| 5+ | 199 (19) | 215 (20) | 467 (19) | 522 (21) |
| Syphilise | 128 (12) | 128 (12) | 4 (0) | 7 (0) |
| HIV at 96 wkf | 65 (6) | 29 (3) | 14 (1) | 7 (0) |
Data are No. (%). To be eligible for the complete-case analysis, trial participants had to have no missing data for the reported variables. Furthermore, participants were restricted to men who have sex with men and a subset of the DISCOVER trial.
Abbreviations: BMI, body mass index; FTC, emtricitabine; HIV, human immunodeficiency virus; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; URAI, unprotected receptive anal intercourse.
aRace was measured through self-classification with an open-ended category (iPrEx, DISCOVER). Due to privacy concerns, data from DISCOVER was collapsed to white versus not white. Therefore, iPrEx was similarly collapsed.
bBMI is presented as mean and standard deviation.
cAlcohol use was defined as self-reported number of drinks on days when drinking (iPrEx) or self-reported alcohol intake in drinks per day (DISCOVER).
dSelf-reported number of unique partners with URAI in the past 84 days (iPrEx) or in the past 90 days (DISCOVER) at enrollment.
eBaseline syphilis diagnosis was determined via rapid plasma reagin and a confirmatory test (iPrEx) or diagnosed per local guidelines (DISCOVER).
fPercentages ignore right censoring.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
